Exploring Opportunities for LNP Delivery in mRNA
PharmaTech
DECEMBER 7, 2024
LNPs have gained solid ground as a drug delivery system for mRNA due to their success in the vaccines arena.
Sat.Dec 07, 2024
59 
Blinatumomab Plus Chemotherapy Improves DFS in Pediatric Patients With SR B-ALL
Pharmacy Times
DECEMBER 7, 2024
In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.
Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Sanofi advances a drug for a rare, platelet-destroying disease
STAT
DECEMBER 7, 2024
(This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here.) Greetings from the always-lovely San Diego. Adam Feuerstein, here, and as you can see from the sunrise photo above, I am still very much on East Coast time. (Nice view from my hotel room, however.
GLP1 Agonists and Dietary Fiber May Reduce VTE Risk and Improve GVHD Outcomes
Pharmacy Times
DECEMBER 7, 2024
Glucagon-like peptide 1 (GLP1) receptor agonists were shown to be associated with a reduced risk of venous thromboembolism (VTE), while high dietary fiber intake was shown to enhance microbiome health, lower graft-versus-host disease (GVHD) severity, and improve overall survival following allogeneic hematopoietic cell transplantation.
Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Opinion: STAT readers on the value of medical comedy, the pediatrician shortage, and more
STAT
DECEMBER 7, 2024
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
More Trending
How does weight loss drug Mounjaro work and why is it in such high demand?
The Guardian - Pharmaceutical Industry
DECEMBER 7, 2024
The King Kong of weight loss drugs will be available on the NHS but only patients with most need will get it Mounjaro, known as the King Kong of weight loss drugs, will be available to patients on the NHS, but this week it was announced the medication will be prioritised to people with the highest needs with the rollout expected to extend over 12 years.
ASH: Cilta-Cel Significantly Increases Minimum Residual Disease Negativity in Lenalidomide-Refractory Multiple Myeloma
Pharmacy Times
DECEMBER 7, 2024
Rakesh Popat, MBBS, PhD explains the mechanisms of action behind the improvement in minimum residual disease in patients with lenalidomide-refractory multiple myeloma with cilta-cel compared with standard of care.
Biocon Announces FDA Approval of Ustekinumab Biosimilar
Big Molecule Watch
DECEMBER 7, 2024
On December 1, 2024, Biocon announced that the FDA has approved YESINTEK (ustekinumab-kfce), a biosimilar to J&Js STELARA. YESINTEK is approved for the treatment of Crohns disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis. According to the announcement, Biocon had entered into a settlement and licensing agreement with Janssen to commercialize YESINTEK in the United States no later than February 22, 2025, upon approval from the FDA.
ASH 2024: Pharmacists Play Key Role in Incorporating Venetoclax, Blinatumomab for Treatment of Hematologic Malignancies
Pharmacy Times
DECEMBER 7, 2024
Amir Ali, PharmD, BCOP highlights the success of shorter-treatment duration venetoclax in patients with acute myeloid leukemia and efficacy of pre-transplant blinatumomab in those with acute lymphocytic leukemia.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
ASH Expert: Axi-Cel Treatment Causes Decreased Incidence, Severity of Toxicities in Large B-Cell Lymphoma
Pharmacy Times
DECEMBER 7, 2024
Jason Wang, MD highlights the reduction in incidence and severity of adverse events such as cytokine release syndrome and ICANS following axi-cel treatment in patients with R/R LBCL.
Let's personalize your content